Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares MSCI China ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.07 (market cap $590.53M), while iShares MSCI China ETF trades at $54.35. The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| DNA | MCHI | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $16.14 | $66.99 |
52-Week Low | $5.48 | $50.48 |
Enterprise Value | $627.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
MCHI trades at $52.53, down 1.13% on the day, with neutral technical signals from both moving averages and oscillators. The ETF shows mixed sentiment amid China's factory rebound driven by AI hardware exports and Beijing's $295 billion AI infrastructure plan. Recent news highlights China's tech sector momentum but also persistent geopolitical tensions with US restrictions on Chinese tech firms.
Outlook remains balanced with AI-driven growth potential offset by value trap risks and regulatory uncertainties. The ETF faces headwinds from US-China tech rivalry but benefits from China's massive domestic AI investment program. Investors should weigh sector-specific opportunities against broader macroeconomic and geopolitical challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
